Plate Nº 92 · recorded November 15, 2026
Health & Medicine ResearchReported finding
Electric Comb Restored Nearly 98% of Hair in Mouse Trials
A bioelectronic comb restored nearly 98% of hair in testosterone-treated mice within 28 days, beating finasteride and minoxidil in early lab tests. Human trials have not begun.
By James Calloway4 min read747 words
In brief
- The Detangle electric comb achieved about 97.85% hair regrowth in mice over 28 days when combined with two gene therapies.
- The device's electric field penetrates roughly 9 times deeper into follicle regions than conventional external application.
- Electrostimulation alone produced about 40% regrowth, below minoxidil's roughly 70%.
- The study, led by Beihang University researchers, was published in Nature Communications.
- All results are from mouse models; no human testing has been reported.
A comb-shaped bioelectronic device restored about 97.85 percent of lost hair in mice within 28 days, according to a new study published in Nature Communications by researchers led by scientists at Beihang University in Beijing. That figure is the headline. The catch, and there is one, is that every result so far comes from mice.
The device, called 'Detangle', is a specialized comb with electronic teeth of two different lengths, embedded with electrodes and drug-carrying modules. Its creators describe how it works in their paper: "This system features electronic teeth embedded with height-differentiated electrodes and integrated drug-loading modules, which generate an enhanced electric field penetrating up to ~9 times deeper into hair follicle regions than conventional external application."
What is the comb actually doing?
Two things at once. First, pulsed electric fields from the alternating teeth stimulate the hair follicles directly. The staggered tooth design matters here: the researchers say the height difference produces an electric field 2.63 times stronger than one from teeth aligned in a single row.
Second, the shorter teeth carry drugs. The pulses drive therapeutic molecules deep into the skin through a process called electroporation — briefly making cell membranes more permeable so molecules can slip inside. Think of it as opening tiny doors in the skin's cells and pushing medicine through them.
The team tested two experimental genetic treatments alongside the electrical stimulation:
- VEGFA plasmid — a piece of DNA that stimulates the growth of blood vessels around hair follicles, feeding them better.
- SRD5A2 siRNA — a molecule that silences a hormone pathway responsible for shrinking follicles.
The target condition is androgenetic alopecia (AGA), the common pattern hair loss estimated to affect over a billion people worldwide.
How did the numbers stack up?
The experiments used male mice with testosterone-induced hair loss, measured over 28 days on shaved patches of their backs. The results break down like this:
- Untreated mice: about 1 percent regrowth.
- Electrostimulation only: about 40 percent.
- Finasteride (oral drug): about 50 percent.
- Minoxidil (topical drug): about 70 percent.
- Detangle plus SRD5A2 siRNA: about 85 percent.
- Detangle plus VEGFA plasmid: about 90 percent.
- Full system — electrostimulation plus both therapies: about 97.85 percent.
Note the middle rows. Electricity alone lost to both conventional drugs. The device only dominated when paired with the experimental gene-based treatments. That detail matters, and it's easy to miss in the excitement over the near-total recovery figure.
The researchers write: "This approach accelerates hair growth nearly 100 percent within a month in the AGA mouse model, surpassing the outcomes achievable with conventional oral or external medications."
What does this change for people losing hair now?
Honestly? Nothing yet. The study is a proof of concept in a mouse model of hair loss, not a clinical trial in humans. Mouse skin, mouse follicles, mouse hormones — none of it translates automatically to the scalps of a billion people. The experimental treatments involved, siRNA and plasmid delivery, are still far from pharmacy shelves in most contexts.
Safety is the other open question. Electroporation temporarily punches holes in cell membranes, and delivering genetic material into human skin would need extensive testing before regulators came anywhere near approval. The study itself, as reported, does not address human safety data — because there isn't any yet.
Why the skepticism is warranted — and why the idea still has legs
The pattern here is familiar. A device shows spectacular results in animals, and the headlines write themselves. Plenty of hair-loss breakthroughs have taken this route and stalled at the human-testing stage. Backs of mice are not human scalps, and testosterone-induced hair loss in a lab is a simplified stand-in for a condition with genetic, hormonal and age-related components.
Still, the underlying engineering is genuinely clever. Combining physical stimulation with targeted drug delivery in one consumer-shaped object — a comb, of all things — solves a real delivery problem. Getting therapeutic molecules deep enough to reach follicles has always been the weak point of topical treatments. An electric field pushing roughly nine times deeper than conventional external application, if it holds up in humans, would be a meaningful advance on its own.
The next step, as always, is human trials. Until those happen and show both safety and efficacy, the Detangle comb remains an intriguing laboratory result rather than a baldness cure. If future testing supports these findings, the humble comb could stage an unexpected comeback. Until then, keep your expectations combed down.
via sciencealert.com (Source)
More from James Calloway
Show full bio
Staff writer covering regulation, policy and their impact on general science news at SciBeat.
389 articles
Nearby plates
- Mouse study: Wireless implant normalized blood sugar without insulin
- Self-Powered Toothbrush Kills Cavity Bacteria With Its Own Electricity
- Chip-sized frequency comb matches lab giants in clock tests
- Motorless Biodegradable Bubble Flees Lactic Acid, Study Shows
- MIT researchers build microfluidic tool to collect living cancer cells